Edition:
United States

Esperion Therapeutics Inc (ESPR.OQ)

ESPR.OQ on NASDAQ Stock Exchange Global Market

48.28USD
28 Jun 2017
Change (% chg)

-- (--)
Prev Close
$48.28
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
439,098
52-wk High
$49.55
52-wk Low
$9.40

ESPR.OQ

Chart for ESPR.OQ

About

Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the... (more)

Overall

Beta: 2.80
Market Cap(Mil.): $1,090.65
Shares Outstanding(Mil.): 22.59
Dividend: --
Yield (%): --

Financials

  ESPR.OQ Industry Sector
P/E (TTM): -- 240.52 19.05
EPS (TTM): -4.47 -- --
ROI: -42.67 -8.03 -5.05
ROE: -42.93 -10.41 -4.28

BRIEF-Esperion reports Q1 net loss per common share $1.80

* Esperion provides Bempedoic Acid development program updates; reports first quarter 2017 financial results

May 04 2017

BRIEF-Boxer Capital reports 5.3 pct passive stake in Esperion Therapeutics

* Boxer Capital LLC reports 5.3 percent passive stake in Esperion Therapeutics Inc as of March 20 - SEC filing Source: (http://bit.ly/2mZu8Mb) Further company coverage:

Mar 23 2017

Wall Street sinks on fears of delays to Trump tax cuts

Wall Street fell sharply on Tuesday as investors worried that President Donald Trump will struggle to deliver promised tax cuts that propelled the market to record highs in recent months, with nervousness deepening ahead of a key healthcare vote. | Video

Mar 21 2017

BRIEF-Esperion announces FDA confirmation to approval for an LDL-C lowering indication for bempedoic acid

* Esperion announces fda confirmation regarding regulatory pathway to approval for an ldl-c lowering indication for bempedoic acid

Mar 20 2017

BRIEF-Esperion initiates of phase 2 triplet oral therapy study

* Esperion announces initiation of phase 2 triplet oral therapy study of bempedoic acid/ezetimibe/atorvastatin

Mar 07 2017

BRIEF-Esperion posts Q4 loss per share $1.29

* Esperion provides bempedoic acid development program update; reports fourth quarter and full year 2016 financial results

Feb 22 2017

BRIEF-Esperion completes enrollment of pivotal phase 3 long-term safety and tolerability study of Bempedoic Acid

* Esperion completes enrollment of pivotal phase 3 long-term safety and tolerability study of bempedoic acid in patients with hypercholesterolemia

Jan 25 2017

More From Around the Web

Earnings vs. Estimates